Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (47)	2/12/1998 6:24:00 PM
From: John S. Sturges	Read Replies (1) of 4974

I believe BVF owns some PDLI. Big news next 5dys. M.Geller at CIBC Oppenheimer reported that data to be given at 2 conferences Feb 14th, Geneva and Feb 18th., Florence, will show Zenapax(a T-Cell inhibitor and organ transplant drug) to be very effective against Uveitis(stopped the disease cold), very effective in liver transplants thus expanding the current market by 80% and superior to Cyclosporin in every manner and is likely to eliminate Cyclosporin form the market place. Further, the data also will show that Zenapax eliminated psoriasis in transplant patients. He believes a psoriasis study in progress will show Zenapax to be very effective without side effects by year end. The market for Zenapax is very large, over $10Billion. PDLI began moving this afternoon as Geller recommended a strong buy, target $70shr. with this information in hand. Best regards, John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next